Skip to main content
Industry News
PET study evaluates breakthrough drug in neuroblastoma

Australian researchers who used PET with Cu-64 CuCl2 found that mice with neuroblastoma that received the new drug dextran-catechin, which cut copper supply to tumors, had significantly reduced tumor growth without a corresponding drop in blood copper levels. The findings in the journal Theranostics suggest that Cu-64 CuCl2 PET may be used to provide personalized cancer treatments and improve cancer drug resistance awareness, researchers said.

Full Story: